title: Curcumin Lowers Serum Lipids and Uric Acid in Subjects With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial.
abstract: BACKGROUND
  Nonalcoholic fatty liver disease (NAFLD) is one of the most common hepatic diseases in the general adult population. Dyslipidemia, hyperuricemia, and insulin resistance are common risk factors and accompanying features of NAFLD. Curcumin is a dietary natural product with beneficial metabolic effects relevant to the treatment of NAFLD.
  
  
  OBJECTIVE
  To assess the effects of curcumin on metabolic profile in subjects with NAFLD.
  
  
  METHODS
  Patients diagnosed with NAFLD (grades 1-3; according to liver sonography) were randomly assigned to curcumin (1000 mg/d in 2 divided doses) (n = 50) or control (n = 52) group for a period of 8 weeks. All patients received dietary and lifestyle advises before the start of trial. Anthropometric measurements, lipid profile, glucose, insulin, glycated hemoglobin, and uric acid concentrations were measured at baseline and after 8 weeks of follow-up.
  
  
  RESULTS
  Eighty-seven subjects (n = 44 and 43 in the curcumin and control group, respectively) completed the trial. Supplementation with curcumin was associated with a reduction in serum levels of total cholesterol (P < 0.001), low-density lipoprotein cholesterol (P < 0.001), triglycerides (P < 0.001), non-high-density lipoprotein cholesterol (P < 0.001), and uric acid (P < 0.001), whereas serum levels of high-density lipoprotein cholesterol and glucose control parameters remained unaltered. Curcumin was safe and well tolerated during this study.
  
  
  CONCLUSIONS
  Results of the present trial suggest that curcumin supplementation reduces serum lipids and uric acid concentrations in patients with NAFLD.
authors.affiliation: *Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran;†Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, Iran;‡Medicine Quran and Health Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran;§Baqiyatallah University of Medical Sciences, Tehran, Iran;¶Biomedical Research Unit, Mexican Social Security Institute, Durango, Mexico;║Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; and**Metabolic Research Centre, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Australia.
authors.forename: Yunes
authors.initials: Y
authors.lastname: Panahi
authors.forename: Parisa
authors.initials: P
authors.lastname: Kianpour
authors.forename: Reza
authors.initials: R
authors.lastname: Mohtashami
authors.forename: Ramezan
authors.initials: R
authors.lastname: Jafari
authors.forename: Luis E
authors.initials: LE
authors.lastname: Simental-Mendía
authors.forename: Amirhossein
authors.initials: A
authors.lastname: Sahebkar
mesh_terms: D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D008076:Cholesterol, HDL / Q000037:antagonists & inhibitors / Q000097:blood*; D008078:Cholesterol, LDL / Q000037:antagonists & inhibitors / Q000097:blood*; D003474:Curcumin / Q000494:pharmacology / Q000627:therapeutic use*; D019587:Dietary Supplements; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D065626:Non-alcoholic Fatty Liver Disease / Q000097:blood* / Q000000981:diagnostic imaging / Q000188:drug therapy; D014527:Uric Acid / Q000037:antagonists & inhibitors / Q000097:blood*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D015415:Biomarkers; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D014527:Uric Acid; D003474:Curcumin